49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03155477 (ClinicalTrials.gov) | June 10, 2016 | 13/5/2017 | Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D | Effect Of Curcuma Xanthorrhiza Supplementation In Systemic Lupus Erythematosus Patients (SLE) With Hypovitamin D Which Were Given Vitamin D3 Towards Disease Activity (SLEDAI), Interleukin-6 (IL-6) And Tumor Growth Factor-ß1 (TGF-ß1) Serum | SLE | Dietary Supplement: Cholecalciferol and C. Xanthorrhiza;Dietary Supplement: Cholecalciferol and placebo | Saiful Anwar Hospital | NULL | Completed | 18 Years | 45 Years | Female | 39 | N/A | NULL |
2 | NCT01709474 (ClinicalTrials.gov) | June 2013 | 16/10/2012 | Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus | Vitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Drug: Vitamin D3 6000 IU;Drug: Vitamin D3 400 IU | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Terminated | 5 Years | 20 Years | All | 7 | Phase 2 | United States |
3 | NCT00710021 (ClinicalTrials.gov) | November 2008 | 1/7/2008 | Vitamin D3 in Systemic Lupus Erythematosus | Effect of Vitamin D3 on the IFN Alpha Signature in Patients With Systemic Lupus Erythematosus (ALE02) | Systemic Lupus Erythematosus;SLE;Lupus | Drug: Vitamin D3;Drug: Vitamin D3 placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Completed | 18 Years | N/A | All | 57 | Phase 2 | United States |